Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin–angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Patients with Type 2 diabetes mellitus (T2DM) are often treated with multiple glucose‐lowering and cardiovascular agents. The concomitant use of nitrates, renin–angiotensin system (RAS) blockers, or insulin has been linked to a potential increase in myocardial ischemic risk with rosiglitazone. The PROactive database provides an opportunity to investigate the effects of these medications on the potential macrovascular benefits reported with pioglitazone. Methods: The PROactive study was a randomized double‐blind prospective trial that evaluated mortality and cardiovascular morbidity in 5238 patients with T2DM and macrovascular disease. Patients received pioglitazone or placebo in addition to their baseline glucose‐lowering and cardiovascular medications. The effect of pioglitazone on composite endpoints was evaluated, including all‐cause death, myocardial infarction (MI), and stroke, as well as safety events of edema and serious heart failure, in subgroups using nitrates, RAS blockers, or insulin at baseline. Results: The risk of all‐cause death, MI, and stroke for pioglitazone versus placebo was similar regardless of the baseline use of nitrates, RAS blockers, or insulin, with hazard ratios ranging from 0.81 to 0.87. Similar results were obtained for the other composite endpoints analyzed. There were no significant interactions between baseline medication subgroups and treatment. The increased risk of edema and serious heart failure was consistent across the baseline medication subgroups. Conclusions: This post hoc analysis did not reveal an increased risk of macrovascular events with pioglitazone in patients receiving nitrates, RAS blockers, or insulin. Rather, all patients realized the same trend towards benefit with pioglitazone, and adverse events of edema and heart failure were predictable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
A desktop guide to Type 2 diabetes mellitus
European Diabetes Policy Group, 1. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00166.x · Cited by 670
Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2070 · Cited by 300
Dagenais (2008) · doi:10.2337/dc07-1868 · Cited by 183
Shuster, J. J., Jones, L. S., & Salmon, D. A. (2007) · Statistics in Medicine · doi:10.1002/sim.3060 · Cited by 105
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Cited by
Kung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
“However, this treatment difference was not reproduced in a post-hoc analysis of the PROactive data [38].”
MethodClinically and pharmacologically relevant interactions of antidiabetic drugs
May, M., & Schindler, C. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816638050 · Cited by 160
Fuentes, B., Amaro, S., Alonso de Leciñana, M., Arenillas, J. F., Ayo-Martín, O., Castellanos, M., Freijo, M., García-Pastor, A., Gomis, M., Gómez Choco, M., et al. (2021) · Neurología · doi:10.1016/j.nrl.2020.04.030 · Cited by 9
Metadata
- Authors
- ERDMANN, E., SPANHEIMER, R., CHARBONNEL, B., & on behalf of the PROactive Study Investigators
- Venue
- Journal of Diabetes
- Publisher
- Wiley
- Published
- 2010-08-16
- Volume
- 2
- Issue
- 3
- Pages
- 212-220
- ISSN
- 1753-0393 (ISSN-L)
- 1753-0407
- OpenAlex
- W2133377772
- Cited by
- 46
- References
- 7
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin–angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). https://app.cochat.ai/papers/10.1111/j.1753-0407.2010.00082.x
- The paper
- ERDMANN, E., SPANHEIMER, R., CHARBONNEL, B., & on behalf of the PROactive Study Investigators. (2010). Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin–angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). Journal of Diabetes. https://doi.org/10.1111/j.1753-0407.2010.00082.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.